Opinion|Videos|December 5, 2024
Behind the Scenes: Patient Education and Decision-Making for CAR T
Panelists discuss how health care providers engage in vital conversations with patients about CAR T therapy, focusing on comprehensive education, emotional support, and clear communication about the treatment journey ahead.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- From your perspective, what are the key conversations you have with patients during this decision-making process? What are the most crucial aspects of patient education and support that you focus on? How do you help patients understand what lies ahead (eg, describe conversations, resources you utilize, etc)?
Advertisement
Related to this article
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Advertisement
Advertisement
Trending on CancerNetwork
1
Building Systems to Catch Liver and Other Cancers in Patients With MASLD
2
Closing the HCC Surveillance Gap in MASLD Without Cirrhosis
3
Rethinking Surveillance and Multidisciplinary Care in MASLD-Related HCC
4
Weighing HCC Surveillance for Patients With MASLD and F3 Fibrosis
5